None listed
Conditions
Interventions
Drug : Patients included in this study were categorized into two groups: the treatment group, using 2% Rebamipide, and the control group, using 0.15% Hyaluronic acid. Over a total treatment period of
Sponsors
Pusan National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: This study included patients who subjectively complained of dry eye symptoms (e.g., dryness, burning sensation, grittiness, or stinging), exhibited a tear break-up time (TBUT) of <= 5 seconds or a strip meniscometry (SM) score of <= 10 mm, were diagnosed with meibomian gland dysfunction (MGD) characterized by moderate-to-severe lid margin telangiectasia or abnormal meibomian gland secretions, and provided written informed consent personally or through a legal representative.
Exclusion criteria
Exclusion criteria: Exclusion criteria included patients with a history of artificial tear use within 2 weeks of enrollment, a history of ocular surgery, or concurrent use of ophthalmic drops for conditions other than dry eye (e.g., glaucoma or allergies); those taking systemic medications that affect tear production (e.g., anxiolytics, antihistamines, or antidepressants); individuals who received dry eye treatments other than artificial tears (e.g., punctal occlusion, cyclosporine, or steroids) within the past 3 months; those with permanent punctal occlusion or periocular infectious diseases; and those unable to understand or provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lid telangiectasia;Meibomian gland secretion;Lipid Layer Thickness | — |
Secondary
| Measure | Time frame |
|---|---|
| Ocular Surface Disease Index;Tear break-up time;Tear secretion (Schirmer test);Corneal and conjunctival staining (NEI);Blinking rate | — |
Countries
Korea, Republic of
Contacts
Public ContactYeonji Jo
Pusan National University Hospital
Outcome results
None listed